Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG640

—

541365f3-8bb6-546d-95a4-973b0f0450ef

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.406
  • HYPOXIA+0.175
  • G2M_CHECKPOINT+0.172
  • E2F_TARGETS+0.152
  • MYC_TARGETS_V1+0.142
  • ANDROGEN_RESPONSE+0.119
  • UV_RESPONSE_DN+0.107
  • UNFOLDED_PROTEIN_RESPONSE+0.090
  • MTORC1_SIGNALING+0.087
  • MITOTIC_SPINDLE+0.079

Top 10 suppressed

  • MYC_TARGETS_V2-0.379
  • MYOGENESIS-0.360
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.359
  • UV_RESPONSE_UP-0.325
  • APICAL_JUNCTION-0.304
  • OXIDATIVE_PHOSPHORYLATION-0.292
  • WNT_BETA_CATENIN_SIGNALING-0.287
  • INTERFERON_ALPHA_RESPONSE-0.281
  • CHOLESTEROL_HOMEOSTASIS-0.267
  • APICAL_SURFACE-0.254

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1ERR2598094
medullo-epn-umap@date-based
fetalfetal0.871
2SJEPD031786_D2.RNA-Seq
medullo-epn-umap@date-based
EPNAnaplastic EPN0.822
3ERR2598089
medullo-epn-umap@date-based
fetalfetal0.786
4C3N-01016
lung-landscapes@6
—cohortA30.781
5MNG636
mng-umap@100
——0.781
6ERR2598093
medullo-epn-umap@date-based
fetalfetal0.778
7SJEPD030795_D2.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.777
8SJEPD030770_D1.RNA-Seq
medullo-epn-umap@date-based
EPNEPN Tumor0.754
9MDT-AP-3311
medullo-epn-umap@date-based
MedMedulloblastoma0.741
10SRR3147744
colon-landscapes@1
——0.739

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 17 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.406Remibrutinib— uncovered
HYPOXIA0.175Idelalisib— uncovered
G2M_CHECKPOINT0.172Inavolisib— uncovered
E2F_TARGETS0.152Inavolisib— uncovered
MYC_TARGETS_V10.142Inavolisib— uncovered
ANDROGEN_RESPONSE0.119Inavolisib— uncovered
UV_RESPONSE_DN0.107Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.090Idelalisib— uncovered
MTORC1_SIGNALING0.087Inavolisib— uncovered
MITOTIC_SPINDLE0.079Inavolisib— uncovered
SPERMATOGENESIS0.066Inavolisib— uncovered
PANCREAS_BETA_CELLS0.053Cobimetinib— uncovered
GLYCOLYSIS0.051Inavolisib— uncovered
KRAS_SIGNALING_UP0.027Inavolisib— uncovered
ANGIOGENESIS0.023Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.012Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.006Inavolisib— uncovered